Nevirapine Adverse Events

Medical Advocates
Nevirapine (Viramune)

Journal Citations: Adverse Events

General Reports
Cardiovascular Disorders
Cutaneous Disorders
Hepatic Disorders
Hypersensitivity
Mental Disorders
Meningoencephalitis
Metabolic Disordersn
Renal Disorders
Oral Disorders
Stevens-Johnson Syndrome/Toxic Epidermal Necrosis

NVP Main Page

Journal Main Page

Main New/Newsworthy

Home Page

Last Update: May 02, 2012
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports

A WEEK-IN-REVIEW FEATURED REPORT
Pharmacogenetics of Toxicity, Plasma Trough Concentration and Treatment Outcome with Nevirapine-Containing Regimen in Anti-Retroviral-Naïve HIV-Infected Adults: an Exploratory Study of the TRIANON ANRS 081 Trial.
Gozalo C, Gérard L, Loiseau P, et al
Basic Clin Pharmacol Toxicol. 2011 Aug 9.
Abstract
Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina.
Bottaro EG, Huberman MJ, Iannella Mdel C, et al
J Int Assoc Physicians AIDS Care 2010 Sep-Oct;9(5):306-12.
Abstract

Amino Acid Adduct Formation by the Nevirapine Metabolite, 12-Hydroxynevirapine
A Possible Factor in Nevirapine Toxicity.
Antunes AM, Godinho AL, Martins IL, et al
Chem Res Toxicol. 2010 Apr 14.
Abstract

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing
antiretroviral therapy.
Kesselring AM, Wit FW, Sabin CA, et al
AIDS. 2009 May 29.
Abstract

Nevirapine Toxicity in Non-HIV Cancer Patients.
Landriscina M, Fabiano A, Lombardi V, et al
Chemotherapy. 2008 Oct 2;54(6):475-478.
Abstract

Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens :
CD4+ T-Cell Count and Gender in Hepatitis C Seropositive and Seronegative Patients.
Torti C, Costarelli S, De Silv
Abstract

Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant
women.
Phanuphak N, Apornpong T, Teeratakulpisarn S, et al
HIV Med. 2007 Sep;8(6):357-66.
Abstract

Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4
count.
Tansuphaswadikul S, Aung SE, Phonrat B, et al
Asian Pac J Allergy Immunol. 2007 Jun-Sep;25(2-3):147-54.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Nevirapine toxicity.
Taiwo BO.
Int J STD AIDS. 2006 Jun;17(6):364-70.
Abstract

Cardiovascular Disorders

Nevirapine and cardiovascular risk.
Parienti JJ, Verdon R.
Med Mal Infect. 2010 Apr 28.
Abstract

FULL-TEXT ARTICLE
Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-
Therapy-Naive Patients Infected with HIV-1
van Leth F, Phanuphak P, Stroes E, et al
PLOS Vol2 Issue 9 Sep 2005
Paper

Cutaneous

FULL-TEXT DOCUMENT
HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients.
Umapathy S, Pawar A, Bajpai S,
J Pharmacol Pharmacother. 2011 Apr;2(2):114-5.
Letter
A WEEK-IN-REVIEW FEATURED REPORT
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among
populations of African, Asian, and European descent.
Yuan J, Guo S, Hall D, et al
AIDS. 2011 Apr 18.
Abstract

HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients.
Likanonsakul S, Rattanatham T, Feangvad S, et al
AIDS Res Ther. 2009 Oct 21;6(1):22.
Abstract

A Model and Risk Score for Predicting Nevirapine-Associated Rash among HIV-infected Patients:
In Settings of Low CD4 Cell Counts and Resource Limitation.
Kiertiburanakul S, Sungkanuparph S, Malathum K
Open AIDS J. 2009 Jul 8;3:24-30.
Abstract

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in
HIV-infected Thai patients.
Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al
Pharmacogenet Genomics. 2009 Dec 19
Abstract

HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
Vitezica ZG, Milpied B, Lonjou C, et al
AIDS. 2008 Feb 19;22(4):540-1.
Abstract

Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients
with CD4 cell counts <250 cells/muL.
Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, et al
Int J STD AIDS. 2007 Nov;18(11):782-786.
Abstract

Nevirapine-related adverse events in a patient receiving a fixed-drug combination pill.
Daniel OJ, Krain AB, Ogun SA, Odusoga OL, Boyle BA.
J Natl Med Assoc. 2005 Dec;97(12):1719-21.
Abstract

Case reports: treatment of nevirapine-associated dress syndrome with intravenous
immune globulin (IVIG).
Fields KS, Petersen MJ, Chiao E, Tristani-Firouzi P.
J Drugs Dermatol. 2005 Jul-Aug;4(4):510-3
Abstract

Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz.
Hartmann M, Brust J, Schuster D, et al
Hautarzt. 2005 Feb 23
Abstract

Incidence and risk factors for rash in Thai patients randomized to regimens with
nevirapine, efavirenz or both drugs.
Ananworanich J, Moor Z, Siangphoe U, et a;
AIDS. 2005 Jan 28;19(2):185-192
Abstract

Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully
with a combination of intravenous immunoglobulins and N-acetylcysteine.
Claes P, Wintzen M, Allard S,
Eur J Intern Med. 2004 Jul;15(4):255-258.
Abstract

Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to
nevirapine therapy:results of the viramune-zyrtec double-blind, placebo-controlled trial.
Launay O, Roudiere L, Boukli N, et al
Clin Infect Dis. 2004 Apr 15;38(8):e66-7|
Abstract

Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by
Non-HIV-Infected Individuals.
Patel SM, Johnson S, Belknap SM, et al
J Acquir Immune Defic Syndr. 2004 Feb 1; 35(2): 120-125
Abstract

Incidence and risk factors for nevirapine-associated rash.
De Maat MM, Ter Heine R, Mulder JW, et al.
Eur J Clin Pharmacol. 2003 Aug 12
Abstract

Failure of a Short-Term Prednisone Regimen to Prevent Nevirapine-Associated Rash:
A Double-Blind Placebo-Controlled Trial: The GESIDA 09/99 Study.
Knobel H, Miro JM, Domingo P, et al.
J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):14-18.
Abstract

Female sex and the use of anti-allergic agents increase the risk of developing
cutaneous rash associated with nevirapine therapy.
Antinori A, Baldini F, Girardi E, et al
AIDS 2001 Aug 17;15(12):1579-81
Abstract

Hepatic Disorders

Urgent liver transplantation for nevirapine-induced acute liver failure: Report of a case and
review of the literature.
Lopez-Delgado JC, Mendiluce RM, Pinol TS, et al
Ann Transplant. 2012 Mar 31;17(1):122-7..
Abstract
FULL-TEXT ARTICLE
Nevirapine Plasma Concentrations Are Associated with Virologic Response and Hepatotoxicity
in Chinese Patients with HIV Infection.
Wang J, Kou H, Fu Q
PLoS One. 2011;6(10):e26739.
Paper

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among
populations of African, Asian, and European descent.
Yuan J, Guo S, Hall D, et al
AIDS. 2011 Apr 18.
Abstract

Nevirapine-associated hepatotoxicity was not predicted by CD4 count >/=250
cells/muL among women in Zambia, Thailand and Kenya.
Peters P, Stringer J, McConnell MS, et al
HIV Med. 2010 Jul 26
Abstract

FULL-TEXT ARTICLE
Vanishing bile duct syndrome in human immunodeficiency virus: nevirapine hepatotoxicity revisited.
Kochar R, Nevah MI, Lukens FJ, et al
World J Gastroenterol. 2010 Jul 14;16(26):3335-8.
Paper

FULL-TEXT PDF ARTICLE
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected
patients with or without viral hepatitis B or C infection in Cameroon.
Tchatchueng Mbougua JB, Laurent C, et al
BMC Public Health. 2010 Mar 1;10(1):105
Paper

Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a
population from Mozambique.
Ciccacci C, Borgiani P, Ceffa S, Sirianni E,
Pharmacogenomics. 2010 Jan;11(1):23-31.
Abstract

Hepatotoxicity in patients prescribed efavirenz or nevirapine.
Brück S, Witte S, Brust J, et al
Eur J Med Res. 2008 Jul 28;13(7):343-8.
Abstract

Risk for immune-mediated liver reactions by nevirapine revisited.
Medrano J, Barreiro P, Tuma P, et al
AIDS Rev. 2008 Apr-Jun;10(2):110-5.
Abstract

Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and
CD4 cell counts.
De Lazzari E, León A, Arnaiz JA, et al
HIV Med. 2008 Apr;9(4):221-6.
Abstract

Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients
with CD4 cell counts less than 250 cells/microL.
Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, et al
J Med Assoc Thai. 2008 Feb;91(2):159-65.
Abstract

Liver transplantation for fulminant hepatitis related to nevirapine therapy.
Buyse S, Vibert E, Sebagh M, et al
Liver Transpl. 2006 Nov 28;12(12):1880-1882
Abstract

Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a
baseline CD4 cell count greater than 250 cells/mul
Manfredi R, Calza L.
AIDS. 2006 Nov 14;20(17):2233-2236.
Abstract

Hepatic failure due to nevirapine treatment for HIV infection.
Katzenstein TL.
Ugeskr Laeger. 2005 Nov 14;167(46):4359.
Abstract

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
Sanne I, Mommeja-Marin H, Hinkle J, et al
J Infect Dis. 2005 Mar 15;191(6):825-9.
Abstract

Severe Leukopenia Associated with Mild Hepatotoxicity in an HIV Carrier Treated
with Nevirapine.
Shahar E, Krivoy N, Weltfriend S, Pollack S.
Jpn J Infect Dis. 2004 Oct;57(5):212-3.
Abstract

The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver
Function Tests.
Almond LM, Boffito M, Hoggard PG, et al
AIDS Res Hum Retroviruses. 2004 Jul;20(7):716-22.
Abstract

Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic
hepatitis C: harmful impact of nevirapine.
Macias J, Castellano V, Merchante N, et al.
AIDS. 2004 Apr 12;18(5):767-774.
Abstract

Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by
Non-HIV-Infected Individuals.
Patel SM, Johnson S, Belknap SM, et al
J Acquir Immune Defic Syndr. 2004 Feb 1; 35(2): 120-125
Abstract

Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and
efavirenz-containing regimens in HIV-infected patients.
Ena J, Amador C, Benito C, Fenoll V. et al
Int J STD AIDS. 2003 Nov;14(11):776-81.
Abstract

Case series of acute hepatitis in a non-selected group of HIV-infected patients on
nevirapine-containing antiretroviral treatment.
De Maat MM, Ter Heine R, Van Gorp EC, et al
AIDS. 2003 Oct 17;17(15):2209-14
Abstract

Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine.
Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V
HIV Clin Trials 2003 Mar-Apr;4(2):115-120
Abstract

Hepatotoxicity Following Nevirapine-Containing Regimens in HIV-1-Infected Individuals.
De Maat M, Mathot R, Veldkamp A, et al.
Pharmacol Res 2002 Sep;46(3):295
Abstract

FULL-TEXT ARTICLE
Hepatic adverse events during highly active antiretroviral therapy containing nevirapine:
a case report.
Gokengin D, Yamazhan T.
Ann Clin Microbiol Antimicrob 2002 Sep 16;1(1):1
Paper

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy:
Role of hepatitis C and B infections.
Sulkowski MS, Thomas DL, Mehta SH, et al.
Hepatology 2002 Jan;35(1):182-9
Abstract

Nevirapine-induced hepatitis: a case series and review of the literature.
Piliero PJ, Purdy B.
AIDS Read 2001 Jul;11(7):379-82
Abstract

Late onset hepatitis and prolonged deterioration in hepatic function associated with
Nevirapine therapy.
Clarke S., Harrington P., Condon C., et al
Int Journal STD AIDS 2000:11:336-337
Abstract

Metabolic Disorders

Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Guaraldi G, Zona S, Orlando G, et al
Clin Drug Investig. 2011 Nov 1;31(11):759-67|
Abstract
Morphological and Metabolic Components of Lipodystrophy in Various Nevirapine-Based Highly Active
Antiretroviral Therapy (HAART) Regimens: A Cross-Sectional, Observational Study.
Guaraldi G, Zona S, Orlando G, et al
Clin Drug Investig. 2011 Sep 15
Abstract

Renal Disorders

Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
Mauss S; Berger F; Schmutz, Guenther , et al
AIDS. 19(1):93-95, January 3, 2005.
Abstract

Hypersensitivity

Nevirapine Hypersensitivity.
Popovic M, Shenton JM, Chen J,
Handb Exp Pharmacol. 2010;196:437-451.
Abstract

HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
Vitezica ZG, Milpied B, Lonjou C, et al
AIDS. 2008 Feb 19;22(4):540-1.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis
C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E, Gutiérrez S, Jahnke N, et al
AIDS. 2007 Jul 31;21(12):1561-156
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench
and back again.
Martin A, Nolan D, Almeida CA, Rauch A, Mallal S.
Pharmacogenomics. 2006 Jan;7(1):15-23.
Abstract

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and
abrogated by low CD4 T-cell counts.
Martin, AM, Nolan, D, James I, et al
AIDS. 19(1):97-99, January 3, 2005.
Abstract

Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with
nevirapine therapy.
Lanzafame M, Rovere P, et al.
Scand J Infect Dis 2001;33(6):475-6
Abstract

Mental Disorders

FULL-TEXT ARTICLE
Neuropsychiatric complications of nevirapine treatment.
Wise MEJ K Mistry, S Reid.
BMJ 2002;324:879 ( 13 April )
Paper

Meningoencephalitis

Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with
nevirapine therapy.
Lanzafame M, Rovere P, et al.
Scand J Infect Dis 2001;33(6):475-6
Abstract

Oral Disorders

Oral adverse effects due to the use of Nevirapine.
Moura MD, Senna MI, Madureira DF, et al
J Contemp Dent Pract. 2008 Jan 1;9(1):84-90.
Abstract

Stevens-Johnson Syndrome/Toxic Epidermal Necrosis

Nevirapine induced Stevens-Johnson syndrome in an HIV infected patient.
Singh H, Kachhap VK, Kumar BN, Nayak K.
Indian J Pharmacol. 2011 Feb;43(1):84-6.
Abstract
Nevirapine-induced Stevens Johnson-syndrome and fulminant hepatic failure requiring
liver transplantation.
Jao J, Sturdevant M, Del Rio Martin J, et al
Am J Transplant. 2010 Jul;10(7):1713-6
Abstract

Fatal outcome of nevirapine-associated toxic epidermal necrolysis.
Leng K, Lonsdorf A, Hartmann M.
Int J STD AIDS. 2008 Sep;19(9):642-3.
Abstract

Nevirapine-induced Stevens-Johnson Syndrome in an HIV Patient.
Jain V, Shome D, Natarajan S. |
Cornea. 2008 Apr;27(3):366-367.
Abstract

Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, , et al.
AIDS 2001 Sep 28;15(14):1843-1848
Abstract

NVP Main Page

Journal Main Page

Main New/Newsworthy

Home Page

Nevirapine Journal Data
Adverse Events